Sign inJoin waitlistJoin the waitlist

KO

Kurt Oettel

Hematology & Medical Oncology Department Chair · Gundersen Lutheran Medical Foundation

Credentials: · · · · ·

History

Gundersen Lutheran Medical Foundation
Present
University of Wisconsin Hospitals and Clinics
Present
University of Wisconsin Hospitals and Clinics
Present

University of Wisconsin Carbone Cancer Center
1998–2000
Internal Medicine
1995–1998
Univ of Wisconsin Sch of Med and Public Health
1991–1995

Research

Specific recognition of human leukemic cells by allogeneic T cells: II. Evidence for HLA-D restricted determinants on leukemic cells that are crossreactive with determinants…
Blood · 1990 · 90 citations
Characteristics and outcome of patients with active pulmonary tuberculosis requiring intensive care
European Respiratory Journal · 2006 · 82 citations
American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care
Journal of Clinical Oncology · 2021 · 80 citations

AT
Anne Traynor
5 papers
Paul Sondel
5 papers
GW
George Wilding
4 papers
Gregory Masters
4 papers
TH
Tien Hoang
4 papers
HA
Harish Ahuja
3 papers
Jeffrey Sosman
3 papers
Maximilian Diehn
3 papers
NP
Nathan Pennell
3 papers
Suresh Ramalingam
3 papers
Bonnie Ky
2 papers
CB
Chandra Belani
2 papers

Grants

Wisconsin NCI Community Oncology Research Program (WiNCORP)
National Cancer Institute · UG1
PI · $32.3M · Marshfield Clinic, Inc.
2014–2027
Gundersen Lutheran Proposal to Join the Community Clinical Oncology Program
National Cancer Institute · U10
Contact PI · $1.1M · Gundersen Lutheran Medical Foundation
2011–2014

Clinical trials

Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer
Site PI · Recruiting · Phase 2
PrECOG, LLC.
2026–2030
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2026–2028
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2025–2030
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2028